WHO ICTRP trial
A study to evaluate the safety and efficacy of Lerociclib in participants with…
EUCTR2021-005238-40-BE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2021-005238-40-BE |
|---|---|
| Public title | A study to evaluate the safety and efficacy of Lerociclib in participants with advanced breast cancer |
| Scientific title | A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants with Advanced Breast Cancer |
| Primary sponsor | EQRx, Inc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Belgium;United States;Moldova, Republic of;Ukraine;Mexico;Italy;Georgia |
| Conditions | Metastatic Breast Cancer MedDRA version: 20.1 Level: PT Classification code 10055113 Term: Breast cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0… |
| Interventions | Trade Name: Lerociclib Product Name: Lerociclib Product Code: EQ132, G1T38 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Lerociclib CAS Number: 2096938-59-3 Other descriptive name: EQ132, G1T38 Concentration unit: mg… |
| Registration date | Mar 14, 2022 |
| Target size | 100 |
| Secondary IDs | EQ132-201;NCT05085002 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: